An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia

This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 in
participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.

Inclusion Criteria:

- Clinical and definitive histologic diagnosis of WM.

- Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd
International Workshop on Waldenström's Macroglobulinemia (IWWM).

- Refractory or relapsed disease to the most recent therapy at study entry unless
participants had intolerance to the most recent therapy. Refractory disease is defined
as not attaining at least a major response, or progressing while on or within 6 months
of completing therapy. Relapsed disease is defined as attaining at least a major
response to therapy and meeting the criteria for disease progression beyond 6 months
after completing therapy.

- Adequate organ function.

Exclusion Criteria:

- Central nervous system (CNS) involvement by WM.

- Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.

- History of other malignancies ≤ 2 years before study entry.

- Uncontrolled active systemic infection or recent infection requiring parenteral
antimicrobial therapy that was completed ≤ 14 days before the first dose of the study
drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.